The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.

ABSTRACT:

Background

CD47 is a broadly expressed cell surface glycoprotein associated with immune evasion. Interaction with the inhibitory receptor signal regulatory protein alpha (SIRPα), primarily expressed on myeloid cells, normally serves to restrict effector function (eg, phagocytosis and immune cell homeostasis). CD47/SIRPα antagonists, commonly referred to as 'macrophage checkpoint' inhibitors, are being developed as cancer interventions. SRF231 is an investigational fully human IgG₄ anti-CD47 antibody that is currently under evaluation in a phase 1 clinical trial. The development and preclinical characterization of SRF231 are reported here.

Methods

SRF231 was characterized in assays designed to probe CD47/SIRPα blocking potential and effects on red blood cell (RBC)

SUBMITTER: Peluso MO 

PROVIDER: S-EPMC7213910 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature